Zevra Therapeutics Total Revenue

The latest total revenue for KMPH is $140M as of June 2026. That compares with $59M in the prior-year period — up 129.3% year over year. That is below the Healthcare sector average of $110B. Investors often review this figure alongside Zevra Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, KMPH's total revenue moved from $59M to $140M — a 129.3% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Zevra Therapeutics's operating scale or balance-sheet position.

Against Healthcare companies, KMPH currently prints $140M for total revenue, while the sector average sits near $110B. That is roughly 99.9% below the sector mean. Large gaps often invite a closer look at Zevra Therapeutics's growth, margins, and balance sheet.

A total revenue figure of $140M for KMPH is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $110B. Explore the charts below for those layers of context.

After noting KMPH's total revenue ($140M), review year-over-year change from $59M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.